Core Viewpoint - Anbiping's stock closed at 30.78 yuan, down 2.66%, with a rolling PE ratio of 1287.16 times, significantly higher than the industry average of 59.32 times [1][2] Company Summary - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows a revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - Anbiping ranks 122nd in the medical device industry based on PE ratio, with the industry median at 39.97 times and the average at 59.32 times [1][2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of August 19, Anbiping's closing price was 31.62 yuan, with a PE ratio of 1322.28, and a total market capitalization of 2.959 billion yuan [1] - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the first quarter of 2025, Anbiping reported a revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, reflecting a year-on-year decline of 238.49% [1] - The gross profit margin for Anbiping was reported at 61.97% [1]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of August 15, Anbiping's closing stock price was 30.22 yuan, with a PE ratio of 1263.74 times, and a total market capitalization of 2.828 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows that Anbiping achieved operating revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the article highlights that Anbiping's stock price closed at 29.63 yuan, down 3.52%, with a rolling PE ratio of 1239.07 times, significantly higher than the industry average of 55.76 times [1] - Anbiping's total market capitalization is reported at 2.772 billion yuan, ranking 122nd in the medical device industry based on PE ratio [1] - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Anbiping's main business focuses on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, indicating that Anbiping's valuation is significantly above industry standards [2]

Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Anbiping, which closed at 31.05 yuan, down 6.87%, with a rolling PE ratio of 1298.45 times, indicating a substantial overvaluation compared to the industry average [1] - Anbiping's total market capitalization is reported at 2.905 billion yuan, which is considerably lower than the industry average market capitalization of 11.731 billion yuan [2] - The company operates in the medical device sector, focusing on tumor screening and diagnostic reagents, automation equipment, and AI-assisted diagnostic software [1] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows that Anbiping achieved a revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.064 million yuan, reflecting a year-on-year decline of 238.49% [1] - The company's gross profit margin stands at 61.97%, indicating a relatively high profitability despite the revenue decline [1]

Company Overview - Anbiping's closing price on August 7 was 33.34 yuan, with an increase of 1.18%, resulting in a rolling PE ratio of 1394.21 times, the lowest in 86 days, and a total market capitalization of 3.12 billion yuan [1] - The company's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic artificial intelligence software [1] Financial Performance - In the first quarter of 2025, Anbiping reported operating revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Anbiping at the 123rd position in the industry ranking [1][2] - Other companies in the industry have significantly lower PE ratios, with the highest being 20.27 times for Sanxin Medical, indicating a substantial disparity compared to Anbiping [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anbiping, a company in the medical device industry, which is currently facing significant challenges reflected in its high PE ratio and declining revenues [1][2] - Anbiping's closing stock price is 31.75 yuan, with a PE ratio of 1327.72, significantly higher than the industry average of 54.56 and the median of 37.54 [1][2] - The company's total market capitalization is 2.971 billion yuan, ranking it 122nd in the industry based on PE ratio [1][2] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1]

Company Overview - Anbiping's closing price on July 11 was 29.62 yuan, up 3.82%, with a rolling PE ratio of 1238.65, marking a new low in 22 days, and a total market capitalization of 2.771 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.0645 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Industry Comparison - The average PE ratio for the medical device industry is 52.06, with a median of 37.22, placing Anbiping at the 122nd position in the industry ranking [1] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.97 for Sanxin Medical [2]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of July 8, Anbiping's closing price was 29.01 yuan, with a PE ratio of 1213.14, and a total market capitalization of 2.714 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49% [1] - The gross profit margin for Anbiping stands at 61.97% [1]

Company Overview - Anbiping's closing price on July 2 was 28.41 yuan, down 3.83%, with a rolling PE ratio of 1188.05 times and a total market value of 2.658 billion yuan [1] - The company operates in the medical device industry, focusing on tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] Financial Performance - For Q1 2025, Anbiping reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1] Shareholder Information - As of March 31, 2025, Anbiping had 10,309 shareholders, an increase of 4,393 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing Anbiping at the 122nd position in the industry ranking [1][2] - Other companies in the industry have significantly lower PE ratios, with the highest being 18.76 times for Antu Biology, indicating a substantial valuation gap [2]